Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238389 | 1.00 | PTGER4 (0.79) | PTGER4 | |
| SCHEMBL5397220 | 0.93 | PTGER4 (0.72) | PTGER4 | |
| SCHEMBL5223597 | 0.89 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL2300769 | 0.85 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL5221211 | 0.84 | PTGER4 (0.87) | PTGER4 | |
| SCHEMBL1735898 | 0.81 | PTGER4 (0.85) | PTGER4 | |
| SCHEMBL3567548 | 0.81 | PTGER4 (0.94) | PTGER4 | |
| SCHEMBL3561049 | 0.81 | PTGER4 (0.94) | PTGER4 | |
| SCHEMBL3561068 | 0.80 | PTGER4 (0.90) | PTGER4 | |
| SCHEMBL3567596 | 0.80 | PTGER4 (0.90) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665351-A1 | IMPROVING GLYMPHATIC-LYMPHATIC EFFLUX | University of Rochester (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2024173675-A1 | IMPROVING GLYMPHATIC-LYMPHATIC EFFLUX | UNIVERSITY OF ROCHESTER (US) | 2024-08-22 | — | — | WO | claimed |
| EP-4711448-A1 | METHOD FOR PROMOTING GENERATION OF MICROVESICLES CONTAINING MITOCHONDRIA AND MEDICAL USE THEREOF | KingBios Co., Ltd. (TW) | 2026-03-18 | — | — | EP | disclosed |
| EP-4665351-A1 | IMPROVING GLYMPHATIC-LYMPHATIC EFFLUX | University of Rochester (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | PROMETHEUS BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024229682-A1 | METHOD FOR PROMOTING GENERATION OF MICROVESICLES CONTAINING MITOCHONDRIA AND MEDICAL USE THEREOF | 台湾君百有限公司 | 2024-11-14 | — | — | WO | disclosed |
| WO-2022138793-A1 | COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTAGONIST | 小野薬品工業株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022138791-A1 | EP2 ANTAGONIST | 小野薬品工業株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022111714-A1 | COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER | 杭州阿诺生物医药科技有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022102731-A1 | CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | 小野薬品工業株式会社 | 2022-05-19 | — | — | WO | disclosed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114375339-A | TL1A patient selection method, system and device | 普罗米修斯生物科学公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3969621-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | Prometheus Biosciences, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114206866-A | Prostaglandin E2Receptor 4 antagonists and uses thereof | 泰昂治疗公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11241454-B2 | Materials and methods to enhance hematopoietic stem cells engraftment procedures | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | TLL1, TSG101, DNASE1L3 | PTGER4 3232/4885 |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | PTGER4 190/4885 |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | DNASE1L3, TLL1, RNASE1 | PTGER4 3553/4885 |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | TLL1, TSG101, DNASE1L3 | PTGER4 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.